Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-07-18 02:02 UTC

BIOMED PULSE

Daily Briefing on Longevity, Viruses & New Cures

Friday, July 18, 2026 — Edition #BPULSE-0718

⚡ TL;DR

The Ebola Bundibugyo virus outbreak in DRC and Uganda has now reached 2,124 confirmed cases and 828 deaths as of July 15, making it the most dangerous active PHEIC on the planet — and the PARTNERS treatment trial, the first ever for this virus strain, only opened patient enrollment July 2. The overall mood is urgent but cautiously active: diagnostics, a treatment trial, and continental response funding are finally in motion, but transmission continues to accelerate. [1] [2] [3]

🦠 OUTBREAKS & VIRUSES

EBOLA BUNDIBUGYO VIRUS — DRC AND UGANDA (ACTIVE PHEIC)

  • As of July 15, 2026, a cumulative total of 2,124 confirmed cases and 828 deaths have been reported from the DRC and Uganda, with sustained cross-border transmission continuing to drive case growth. [1]
  • The WHO declared this outbreak a Public Health Emergency of International Concern (PHEIC) on May 22, 2026, after the IHR Emergency Committee confirmed the Bundibugyo virus etiology first identified in Mongbwalu Health Zone, Ituri Province, DRC on May 14. [4] [5]
  • Africa CDC and WHO launched a joint continental preparedness and response plan on June 5, aiming to raise USD 518 million to support African countries in containing the outbreak. [3]
  • WHO issued its first-ever comprehensive clinical management guidelines for filovirus disease — covering all Ebola and Marburg virus types — on June 17, directly in response to this outbreak. [6]
  • On July 2, WHO added the first molecular diagnostic test for Bundibugyo virus (BDBV) to its Emergency Use Listing; the test detects viral genetic material in blood samples for rapid, accurate confirmation. [7]
  • CDC has activated enhanced Ebola airport entry screening at Washington-Dulles International Airport (May 21) and Atlanta Hartsfield-Jackson (May 23) for travelers arriving from affected regions. [8] [9]
  • A CDC statement dated July 10 confirms the agency remains in active response coordination with DRC and Ugandan health authorities. [10]

ANDES HANTAVIRUS — M/V HONDIUS CRUISE SHIP, MULTI-COUNTRY

  • WHO's fifth Disease Outbreak News report (July 2) on the Andes hantavirus (ANDV) outbreak linked to the cruise ship M/V Hondius confirmed additional cases since the previous report of May 28; the outbreak was first notified to WHO on May 2 with seven initial cases aboard a 147-person vessel.
  • CDC's most recent hantavirus response transcript was published June 24, 2026, indicating ongoing monitoring of this multi-country event.
  • ANDV causes hantavirus pulmonary syndrome, a severe respiratory illness with high case-fatality; person-to-person transmission of ANDV, unlike most hantaviruses, is a documented concern.

NIPAH VIRUS — INDIA (KERALA)

  • On June 11, 2026, Kerala State Health Department confirmed one laboratory-confirmed Nipah virus (NiV) case in Kozhikode district — an adult male with symptom onset May 30 and hospitalization June 10, presenting with neurological symptoms.
  • A separate NiV case was confirmed in Rajshahi Division, Bangladesh on February 3, 2026, involving fever and neurological symptoms with onset January 21.
  • Nipah virus has a case-fatality rate of 40-75% and no licensed treatment; both cases underscore the persistent zoonotic spillover risk in South Asia.

MPOX — RECOMBINANT STRAIN, GLOBAL

  • WHO reported in February 2026 two documented cases of a recombinant monkeypox virus (MPXV) strain comprising genetic elements of both clade Ib and clade IIb, arising through natural co-infection and genetic exchange.
  • Recombination between these two clades — clade Ib associated with higher severity and clade IIb driving the 2022-2023 global outbreak — is being closely monitored for potential changes in transmissibility or virulence.

WEST NILE VIRUS — UNITED STATES

  • CDC issued a July 1, 2026 alert warning of an early and record-pace West Nile virus season in the United States, urging Americans to use mosquito repellents and protective clothing, particularly over the July 4th holiday weekend.

MEASLES — BANGLADESH (ACTIVE OUTBREAK)

  • WHO reported April 23, 2026 that Bangladesh notified a nationwide measles surge affecting 58 of 64 districts, with 19,161 suspected cases and 2,897 laboratory-confirmed cases spanning all eight national divisions.

YELLOW FEVER — GLOBAL SIGNAL

  • From January 1 to May 26, 2026, six countries reported 79 human yellow fever infections, following elevated transmission in the Americas throughout 2025 that persisted into this year; WHO published a global DON on June 24.

AVIAN INFLUENZA A(H9N2) — ITALY

  • Italy notified WHO in late March 2026 of one human A(H9N2) case in an adult male returning from Senegal; next-generation sequencing confirmed the H9N2 subtype; the case is considered a sporadic zoonotic spillover.

GLOBAL IMMUNIZATION SIGNAL

  • WHO and UNICEF report that in 2025, 90% of infants globally (roughly 116 million) received at least one DTP dose and 85% (110 million) completed the full three-dose series, reflecting modest forward progress despite conflict zones and vaccine hesitancy.

🧬 LONGEVITY & AGING

NAD+ RESTORATION FOR AGED BONE REPAIR

  • A new study (Bioactive Materials, June 27, 2026) describes a senescent metabolism-modulating hierarchical scaffold engineered to restore NAD+ homeostasis and redox balance in aged bone tissue, addressing the energy deficit that impairs healing in elderly patients.
  • Cellular senescence depletes NAD+, a cofactor critical for DNA repair and mitochondrial function; restoring NAD+ in senescent bone-repair cells is an emerging strategy in the geroscience toolkit.

KAEMPFEROL FROM MORINGA OLEIFERA AND LIFESPAN EXTENSION

  • Research published June 25, 2026 (Toxicology Reports) found that kaempferol — a flavonoid isolated from Moringa oleifera — extended longevity and reversed efavirenz-induced functional senescence in Drosophila melanogaster, a standard aging model organism.
  • The finding is notable because efavirenz (an antiretroviral) can accelerate senescence phenotypes; kaempferol appears to counteract this via antioxidant and anti-senescence mechanisms.

TAU, EMERIN, AND NEURODEGENERATION LINK

  • A July 7, 2026 paper (Nucleus journal) identified that the mechanically sensitive nuclear envelope protein emerin is elevated in tau-bearing neurons, linking nuclear mechanotransduction to tau-induced cytoskeletal remodeling — a potential early pathway in tauopathies such as Alzheimer's disease.

DELIRIUM AS A BRIDGE BETWEEN INFECTION AND DEMENTIA

  • Two commentaries in Lancet Healthy Longevity (published ahead of print, indexed June 2026) argue that delirium triggered by severe infections may be the mechanistic missing link explaining why serious infectious illness significantly elevates subsequent dementia risk in older adults.
  • The proposed mechanism involves neuroinflammatory cascades initiated during systemic infection that persist as synaptic and neuronal damage long after the acute episode resolves.

DEMENTIA PREVENTION — READINESS GAPS

  • A Lancet Healthy Longevity perspective (Beeri and Gu, indexed June 2026) calls for pragmatic, real-world-ready dementia prevention strategies, noting that emerging pharmacological and lifestyle tools must be deployable across diverse, under-resourced populations to have global impact.

HYPERTENSION-FRAILTY LINK IN OLDER ADULTS — INDIA

  • A letter published in Blood Pressure (July 7, 2026) highlights evidence from the Longitudinal Ageing Study in India that hypertension is significantly associated with frailty among middle-aged and older Indian adults, reinforcing blood pressure control as a longevity intervention in low- and middle-income countries.

BLUE LIGHT PHOTOAGING — COLLAGEN XVII PROTECTION

  • A July 16, 2026 study in Annals of Medicine showed that recombinant human collagen XVII protects epidermal stem cells from blue-light-induced photoaging by downregulating the Notch signaling pathway, offering a potential topical or cosmetic anti-aging strategy.

CANCER SURGE WARNING — WHO GLOBAL PROJECTION

  • WHO reported July 8, 2026 that new global cancer cases could nearly double by 2050, from an estimated 20.6 million new cases and close to 10 million deaths annually today, driven by aging populations, obesity, and tobacco exposure.

PHYSICAL ACTIVITY RESTRICTION AND MORTALITY — JAPAN

  • An ecological panel study across Japan's 47 prefectures (2013-2022) published in Dialogues in Health (June 11, 2026) found that structural restrictions on physical activity were associated with increased cerebrovascular and diabetes mortality and higher long-term care utilization, with COVID-19 pandemic-era restrictions worsening these outcomes.

💊 NEW CURES & APPROVALS

  • LEQEMBI IQLIK (lecanemab-irmb), sponsor Eisai Inc, received a supplemental FDA approval action (SUPPL AP), representing a new formulation update for this anti-amyloid beta antibody approved for early Alzheimer's disease.
  • VERZENIO (abemaciclib), sponsor Eli Lilly and Co, received a supplemental FDA approval; abemaciclib is a CDK4/6 inhibitor indicated for hormone receptor-positive, HER2-negative breast cancer.
  • PADCEV (enfortumab vedotin-ejfv), sponsor Astellas, received a supplemental FDA approval; this antibody-drug conjugate targets Nectin-4 and is indicated for locally advanced or metastatic urothelial cancer.
  • RINVOQ LQ (upadacitinib), sponsor AbbVie, received a supplemental approval for its liquid formulation; upadacitinib is a JAK1-selective inhibitor used in rheumatoid arthritis, atopic dermatitis, and other inflammatory conditions.
  • XELSTRYM (dextroamphetamine), sponsor Noven Pharms Inc, received a supplemental FDA approval; this is a transdermal patch formulation for ADHD treatment.
  • GLEEVEC (imatinib mesylate), sponsor Novartis, received a supplemental FDA approval; imatinib is the foundational BCR-ABL tyrosine kinase inhibitor for chronic myeloid leukemia and certain gastrointestinal stromal tumors.

Note: All items above reflect supplemental approvals (SUPPL AP) per openFDA Drugs@FDA records; these represent label expansions, new formulations, or manufacturing updates rather than entirely new molecular entities. Dates were not available in the source records.

🧪 CLINICAL TRIALS

PARTNERS TRIAL — FIRST-EVER BUNDIBUGYO VIRUS TREATMENT STUDY

  • Patient enrollment began July 2, 2026 in the DRC for the PARTNERS clinical trial, an international effort to evaluate the first potential therapeutic agents against Ebola disease caused by Bundibugyo virus, for which no approved treatment currently exists. [2]
  • WHO convened expert groups in late May to assess candidate vaccines and therapeutics for Bundibugyo virus before the trial opened, ensuring candidate selection was evidence-guided.

DOCETAXEL PLUS SX-682 — HEAD/NECK AND PROSTATE CANCER (NCT07667400)

  • A new ClinicalTrials.gov-registered study (posted July 17, 2026) is evaluating docetaxel combined with SX-682, a CXCR1/2 inhibitor designed to overcome immunosuppressive tumor microenvironments, in recurrent/metastatic head and neck squamous cell carcinoma, salivary gland carcinoma, and advanced prostate cancer.

TRIPTORELIN FOR OVARIAN PROTECTION IN YOUNG CANCER PATIENTS (NCT06513962)

  • A Phase III trial registered on ClinicalTrials.gov is comparing triptorelin versus no triptorelin for preventing ovarian damage from alkylating-agent chemotherapy in adolescents and young adults with cancer — addressing fertility preservation in a vulnerable population.

IL-15 SUPERAGONIST N-803 WITH OR WITHOUT ETBX-071 VACCINE — PROSTATE CANCER (NCT07686380)

  • A registered trial is evaluating N-803 (an IL-15 superagonist) alone or in combination with the ETBX-071 vaccine in men with biochemically recurrent prostate cancer following stereotactic body radiation therapy, targeting PSA reduction in 30,000-50,000 affected patients per year in the US.

BELINOSTAT PHARMACOKINETICS — UGT1A1 GENOTYPE-DIRECTED (NCT06406465)

  • A pharmacogenomic trial is investigating belinostat dosing guided by UGT1A1 genotype, combined with etoposide and cisplatin, in patients with high-grade neuroendocrine carcinomas — aiming to reduce toxicity in slow metabolizers.

LONG-COVID BRAIN FOG — NUTRITIONAL INTERVENTION (NCT05705648)

  • An ongoing trial is studying the natural course of brain fog complaints in adults aged 22-50 with long-COVID and testing whether supplemental dietary oil can reduce cognitive symptoms, tracking both trajectory and treatment effect.

FUNGAL INFECTION IMAGING — [18F]-FLUOROCELLOBIOSE PET TRACER (NCT07704333)

  • A first-in-human pharmacokinetics study is assessing the novel radioactive PET tracer [18F]FCB for imaging invasive mold infections; currently no imaging scan can visualize systemic fungal infections, and roughly 3.8 million people die with such infections annually.

📢 PUBLIC HEALTH

SALMONELLA — FROZEN SPROUTED BEANS (NEW ALERT, JULY 17, 2026)

  • CDC warns of a Salmonella outbreak linked to frozen sprouted beans, with 11 people from 10 states sickened with the same strain as of July 17, 2026; consumers should check freezers and discard recalled product.

LISTERIA — REQUESON/SOFT RICOTTA CHEESE

  • CDC issued a warning on June 5, 2026 of a Listeria monocytogenes outbreak linked to requesón/soft ricotta cheese; at-risk groups including pregnant women, older adults, and immunocompromised individuals should avoid the implicated product.

E. COLI — FROZEN BLUEBERRIES (JULY 7, 2026)

  • CDC issued a food safety alert on July 7, 2026 warning of an E. coli outbreak linked to frozen blueberries, urging consumers not to eat recalled product.

INFANT BOTULISM — NARA ORGANICS FORMULA

  • CDC issued a June 13, 2026 outbreak update urging parents to immediately stop using all Nara Organics Whole Milk Organic Infant Formula following its linkage to infant botulism cases — the first-ever infant botulism outbreak tied to powdered infant formula in US records.

NEW WORLD SCREWWORM — CDC EMERGENCY OPERATIONS CENTER ACTIVATED

  • CDC activated its Emergency Operations Center for a New World Screwworm (Cochliomyia hominivorax) response on June 12, 2026; the parasitic fly larva can infest living tissue in humans and animals.

GLOBAL FOOD SAFETY — WHO NEW BURDEN DATA

  • WHO reported June 4, 2026 that unsafe food causes 866 million illnesses and 1.5 million deaths annually worldwide, with children under 5 facing nearly three times the illness risk of older individuals.

TRACHOMA ELIMINATION — EL SALVADOR

  • WHO validated El Salvador on July 13, 2026 as having eliminated trachoma as a public health problem; trachoma is the world's leading infectious cause of preventable blindness.

HEALTHCARE-ASSOCIATED INFECTIONS — US DECLINE

  • CDC data released July 15, 2026 show a decline in healthcare-associated infections (HAIs) in 2023 US hospitals, highlighting improved patient safety practices — though drug-resistant pathogens remain a continuing threat.

BIOMED PULSE is an informational summary for educational purposes only and does not constitute medical advice. Always consult qualified healthcare professionals for personal health decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  2. Patient enrolment begins in a scientific trial to identify the… — WHO News
  3. Africa CDC and WHO launch joint continental Ebola response plan — WHO News
  4. First meeting of the IHR Emergency Committee regarding the epi… — WHO News
  5. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  6. WHO issues comprehensive guidelines on filovirus disease, incl… — WHO News
  7. WHO adds first diagnostic test for Ebola Bundibugyo virus to i… — WHO News
  8. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
  9. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
  10. CDC Statement on Ebola Outbreak in the Democratic Republic of … — CDC Newsroom

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260718-02-v31 · 2026-07-18 02:02 UTC · pulse.uzylab.com

Read next